The Gold Dot NR2 Antibody assay is a serological enzyme-linked immunosorbent assay (ELISA) for the quantitative determination of antibodies to the NR2 subunit of human NMDA glutamate receptor in serum. The test is intended to be used in conjunction with clinical evaluation and radiological methods for diagnosis of transient ischemic attack (TIA) and ischemic stroke vs stroke-like disorders. The Gold Dot NR2 Antibody ELISA indicates prior isolated or multiple ischemic stroke and increased risk of near-term cerebral ischemic events in patients with preexisting conditions (diabetes, hypertension, atherosclerosis, cardiovascular disorders). The test allows differentiation between ischemic and hemorrhagic stroke.